Anti-EGFR therapies are used for other tumor types, including colorectal cancers (CRCs) with wt RAS and BRAF, which are treated with anti-EGFR monoclonal antibodies, such as cetuximab or panitumumab. This evidence concerns the gene BRAF and neoplasm.